Literature DB >> 16199894

BRAF copy number gains in thyroid tumors detected by fluorescence in situ hybridization.

Raffaele Ciampi1, Zhaowen Zhu, Yuri E Nikiforov.   

Abstract

Point mutation of the BRAF gene is a common genetic event in papillary thyroid carcinomas. More recently, it has been found that BRAF can also participate in chromosomal rearrangement. In this study, we explore yet another possible mechanism of BRAF alteration, which involves copy number gain. Using fluorescence in situ hybridization with BRAF specific and chromosome 7 centromeric probes, we studied 62 follicular thyroid tumors and 32 papillary carcinomas. We found that numerical changes in BRAF copy number were rare in papillary thyroid carcinomas, while they occurred in 16-45% of follicular tumors of conventional and oncocytic (Hürthle cell) types. They were due to amplification of the gene or gain of one or more copies of chromosome 7. Tetrasomy for chromosome 7 was overall the most common finding. The changes in BRAF copy number did not overlap with RAS mutations in follicular tumors. In a group of follicular carcinomas, tumors with BRAF copy number gain were significantly more often widely invasive (67%) compared to tumors with no copy number change (18%). By Western blotting, the tumors carrying four copies of the gene revealed higher expression of BRAF protein, suggesting that copy number gain may represent another mechanism of BRAF activation in thyroid tumors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16199894     DOI: 10.1385/ep:16:2:099

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  13 in total

Review 1.  Oncogenes and thyroid cancer.

Authors:  G Vecchio; M Santoro
Journal:  Clin Chem Lab Med       Date:  2000-02       Impact factor: 3.694

2.  Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.

Authors:  Paul T C Wan; Mathew J Garnett; S Mark Roe; Sharlene Lee; Dan Niculescu-Duvaz; Valerie M Good; C Michael Jones; Christopher J Marshall; Caroline J Springer; David Barford; Richard Marais
Journal:  Cell       Date:  2004-03-19       Impact factor: 41.582

3.  Chromosomal changes in thyroid tumors. Relation with DNA content, karyotypic features, and clinical data.

Authors:  J R Teyssier; F Liautaud-Roger; D Ferre; M Patey; J Dufer
Journal:  Cancer Genet Cytogenet       Date:  1990-12

Review 4.  Mitogen-activated protein kinase pathways.

Authors:  M J Robinson; M H Cobb
Journal:  Curr Opin Cell Biol       Date:  1997-04       Impact factor: 8.382

5.  Cytogenetic investigations of 340 thyroid hyperplasias and adenomas revealing correlations between cytogenetic findings and histology.

Authors:  G Belge; L Roque; J Soares; S Bruckmann; B Thode; E Fonseca; A Clode; S Bartnitzke; S Castedo; J Bullerdiek
Journal:  Cancer Genet Cytogenet       Date:  1998-02

6.  High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.

Authors:  Edna T Kimura; Marina N Nikiforova; Zhaowen Zhu; Jeffrey A Knauf; Yuri E Nikiforov; James A Fagin
Journal:  Cancer Res       Date:  2003-04-01       Impact factor: 12.701

Review 7.  Molecular pathobiology of thyroid neoplasms.

Authors:  Giovanni Tallini
Journal:  Endocr Pathol       Date:  2002       Impact factor: 3.943

8.  RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma.

Authors:  Marina N Nikiforova; Roy A Lynch; Paul W Biddinger; Erik K Alexander; Gerald W Dorn; Giovanni Tallini; Todd G Kroll; Yuri E Nikiforov
Journal:  J Clin Endocrinol Metab       Date:  2003-05       Impact factor: 5.958

9.  BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC.

Authors:  Paula Soares; Vítor Trovisco; Ana Sofia Rocha; Jorge Lima; Patrícia Castro; Ana Preto; Valdemar Máximo; Tiago Botelho; Raquel Seruca; Manuel Sobrinho-Simões
Journal:  Oncogene       Date:  2003-07-17       Impact factor: 9.867

10.  Mutations of the BRAF gene in human cancer.

Authors:  Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal
Journal:  Nature       Date:  2002-06-09       Impact factor: 49.962

View more
  14 in total

Review 1.  Alterations of the BRAF gene in thyroid tumors.

Authors:  Raffaele Ciampi; Yuri E Nikiforov
Journal:  Endocr Pathol       Date:  2005       Impact factor: 3.943

2.  Utility of BRAF protein overexpression in predicting the metastasis potential of papillary thyroid carcinoma.

Authors:  Lu Feng; Mei Li; Qiu-Ping Zhang; Zheng-Ai Piao; Zhao-Hui Wang; Shen Lv
Journal:  Oncol Lett       Date:  2010-11-23       Impact factor: 2.967

3.  Genomic dissection of Hurthle cell carcinoma reveals a unique class of thyroid malignancy.

Authors:  Ian Ganly; Julio Ricarte Filho; Stephanie Eng; Ronald Ghossein; Luc G T Morris; Yupu Liang; Nicholas Socci; Kasthuri Kannan; Qianxing Mo; James A Fagin; Timothy A Chan
Journal:  J Clin Endocrinol Metab       Date:  2013-03-29       Impact factor: 5.958

4.  Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.

Authors:  Pippa Newell; Sara Toffanin; Augusto Villanueva; Derek Y Chiang; Beatriz Minguez; Laia Cabellos; Radoslav Savic; Yujin Hoshida; Kiat Hon Lim; Pedro Melgar-Lesmes; Steven Yea; Judit Peix; Kemal Deniz; M Isabel Fiel; Swan Thung; Clara Alsinet; Victoria Tovar; Vincenzo Mazzaferro; Jordi Bruix; Sasan Roayaie; Myron Schwartz; Scott L Friedman; Josep M Llovet
Journal:  J Hepatol       Date:  2009-06-12       Impact factor: 25.083

5.  Genomic differences in benign and malignant follicular thyroid tumours using 1-Mb array-comparative genomic hybridisation.

Authors:  Abdul A Qureshi; V P Collins; P Jani
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-04-13       Impact factor: 2.503

6.  Follicular histotypes of oncocytic thyroid carcinomas do not carry mutations of the BRAF hot-spot.

Authors:  Petra B Musholt; Thomas J Musholt; Saskia C Morgenstern; Karl Worm; Sien-Yi Sheu; Kurt W Schmid
Journal:  World J Surg       Date:  2008-05       Impact factor: 3.352

7.  Application of a BRAF pyrosequencing assay for mutation detection and copy number analysis in malignant melanoma.

Authors:  Cynthia Spittle; M Renee Ward; Katherine L Nathanson; Phyllis A Gimotty; Eric Rappaport; Marcia S Brose; Angelica Medina; Richard Letrero; Meenhard Herlyn; Robin H Edwards
Journal:  J Mol Diagn       Date:  2007-08-09       Impact factor: 5.568

8.  Integrated Genomic Analysis of Hürthle Cell Cancer Reveals Oncogenic Drivers, Recurrent Mitochondrial Mutations, and Unique Chromosomal Landscapes.

Authors:  Ian Ganly; Vladimir Makarov; Shyamprasad Deraje; YiYu Dong; Ed Reznik; Venkatraman Seshan; Gouri Nanjangud; Stephanie Eng; Promita Bose; Fengshen Kuo; Luc G T Morris; Inigo Landa; Pedro Blecua Carrillo Albornoz; Nadeem Riaz; Yuri E Nikiforov; Kepal Patel; Christopher Umbricht; Martha Zeiger; Electron Kebebew; Eric Sherman; Ronald Ghossein; James A Fagin; Timothy A Chan
Journal:  Cancer Cell       Date:  2018-08-13       Impact factor: 31.743

9.  Relationship between TSHR, BRAF and PIK3CA gene copy number variations and thyroid nodules.

Authors:  Xiaoli Shi; Mengying Qu; Xing Jin; Lixiang Liu; Fangang Meng; Hongmei Shen
Journal:  Endocrine       Date:  2021-01-11       Impact factor: 3.633

10.  DNA breaks at fragile sites generate oncogenic RET/PTC rearrangements in human thyroid cells.

Authors:  M Gandhi; L W Dillon; S Pramanik; Y E Nikiforov; Y-H Wang
Journal:  Oncogene       Date:  2010-01-25       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.